Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 11.85B |
| Revenue (ttm) | 943.71M |
| Net Income (ttm) | -381.39M |
| Shares Out | 165.19M |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,396,048 |
| Open | 72.71 |
| Previous Close | 72.23 |
| Day's Range | 71.18 - 73.10 |
| 52-Week Range | 29.42 - 86.74 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 93.14 (+29.81%) |
| Earnings Date | Apr 29, 2026 |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for IONS stock is "Strong Buy." The 12-month stock price target is $93.14, which is an increase of 29.81% from the latest price.
News
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Appl...
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexa...
Ionis to hold first quarter 2026 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first qua...
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patien...
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application...
Ionis Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Multiple new launches and pivotal readouts are expected in 2024, including TRYNGOLZA for sHTG and several phase III data releases in cardiology and neurology. Pricing strategies are evolving to maximize access and value, with peak sales for key assets projected in the billions.
Ionis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
TRYNGOLZA's strong launch and upcoming SHTG expansion set up a transformative 2026, with robust clinical data and first-mover advantage driving growth. Strategic pricing, payer negotiations, and international partnerships support multi-billion dollar opportunities, while innovation in oligonucleotide therapeutics aims to maintain leadership amid rising competition.
Ionis announces changes to Board of Directors
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retirin...
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,...
Ionis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
2026 is set for significant growth with multiple product launches, key FDA decisions, and major phase III data readouts across rare disease, neurology, and cardiovascular portfolios. Commercial strategies focus on maximizing value and access, while robust clinical data support broad adoption and future expansion.
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for heredi...
Ionis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
FDA granted priority review for olezarsen in sHTG, enabling a potential mid-year launch. Multiple late-stage pipeline assets are set for approvals and launches through 2027, with a focus on high-risk sHTG patients and continued expansion in neurology. Financial guidance will be updated to reflect accelerated timelines.
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Dru...
Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32
Ionis Pharmaceuticals Earnings Call Transcript: Q4 2025
Revenue grew 34% year-over-year to $944 million, driven by strong launches of TRYNGOLZA and DAWNZERA, and robust pipeline progress. 2026 guidance projects 20% growth, with Olezarsen and zilganersen launches expected to further accelerate revenue and value creation.
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended December 3...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th...
Ionis updates time for fourth quarter and full year 2025 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live w...
Ionis to hold fourth quarter and full year 2025 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourt...
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (don...
Ionis Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant progress was highlighted, including successful launches of Tringulza and Donzera, strong clinical data for Olezarsen, and a robust late-stage pipeline in cardiometabolic and neurological diseases. Upgraded revenue guidance and multiple upcoming launches position the company for sustained growth.
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected...
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ol...
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safet...